Does coronary calcium scoring improve cardiovascular risk prediction?

Does coronary calcium scoring improve risk prediction?

Yes, it does. Coronary artery calcium (CAC) scoring—a quick, low-radiation CT scan that measures calcified plaque in the heart's arteries—consistently adds predictive power to traditional risk factor-based models. A 2022 meta-analysis of 6 cohort studies (over 17,000 participants) found that adding CAC to standard risk calculators (like the Framingham Risk Score or Pooled Cohort Equations) improved the C-statistic (a measure of how well a model separates people who will have events from those who won't) by an average of 0.036 [2]. While this gain may seem modest, it translates into meaningful reclassification: in a large US study (MESA), adding CAC to the Pooled Cohort Equations improved the C-statistic by 0.09 and yielded a net reclassification improvement of 19%, meaning nearly 1 in 5 people were moved to a more accurate risk category [5].

The improvement is especially clear in specific populations. For example, in a study of over 66,000 primary prevention patients, CAC strongly predicted sudden cardiac death, with a stepwise increase in risk as CAC rose (hazard ratio 4.9 for CAC >1000 vs. CAC=0), and this added value was most pronounced in those with low-to-intermediate 10-year risk (<7.5% and 7.5-20%) [6]. Similarly, in a cohort of over 46,000 people without diabetes or prior heart disease, CAC was the single strongest predictor when added to the SCORE2 algorithm [9].

Who benefits most from CAC scoring?

CAC scoring is most valuable for people at intermediate risk (10-20% 10-year risk of a heart attack or stroke), where the decision to start statins is often uncertain. In these patients, a CAC score of zero can safely downgrade risk, while a high score (e.g., >100) can upgrade risk and justify more aggressive treatment. For example, in a Thai cohort of nearly 7,000 asymptomatic patients, those initially classified as intermediate risk but with CAC ≥100 had a 3-fold higher risk of cardiovascular events, and adding CAC improved the C-statistic from 0.703 to 0.716 [4].

CAC also adds value in specific high-risk groups. In patients with familial hypercholesterolemia (a genetic condition causing very high cholesterol), adding CAC to the SAFEHEART risk equation improved the area under the curve (AUC) from 0.793 to 0.884 and yielded a net reclassification improvement of 45.4% [3]. In people with obesity (BMI ≥30), CAC ≥300 was associated with a 3.5-fold higher risk of cardiovascular death and a 5.4-fold higher risk of coronary heart disease death, even after adjusting for traditional risk factors [8]. And in firefighters—a group at high risk for sudden cardiac death—39% had detectable CAC, and 93% of those with CAC had an atherosclerotic cardiovascular disease (ASCVD) risk score below 7.5%, meaning CAC identified risk that traditional scores missed [11].

What are the limitations and trade-offs?

While CAC scoring improves risk prediction, the benefit is not uniform, and there are important caveats. First, the gain in discrimination is modest in some populations. The 2022 meta-analysis noted that the pooled gain in C-statistic was 0.036, and among people reclassified as higher risk by CAC, 85-96% did not actually have an event during follow-up (5-10 years), meaning many people may be reclassified upward without necessarily benefiting [2]. The same analysis concluded that the modest gain may be outweighed by costs, incidental findings, and radiation exposure, and that no evidence yet shows that adding CAC improves clinical outcomes [2].

Second, the predictive value of CAC is not simply about the total score—the density of the calcium matters. A 2024 meta-analysis of 5 studies found that higher CAC density (more compact, dense calcium) was actually associated with lower cardiovascular risk (hazard ratio 0.80 per standard deviation increase), after adjusting for total calcium volume [1]. This means that a high Agatston score driven by dense calcium may be less dangerous than the same score driven by a larger area of less dense calcium. A separate analysis from MESA confirmed that at low calcium volumes (≤130 mm³), higher density was protective (hazard ratio 0.57 per unit of density), but this effect was not significant at higher volumes [7]. This complexity is not captured by the standard Agatston score and may lead to over- or under-estimation of risk in some patients.

Third, the evidence for clinical benefit (i.e., that CAC-guided treatment actually reduces heart attacks or deaths) is still lacking. While one study showed that removing the cost barrier for CAC led to increased statin use and improved cholesterol levels [10], no randomized trial has yet demonstrated that using CAC to guide therapy improves hard outcomes like mortality or myocardial infarction compared to standard risk-based treatment [2].

About These Sources

This answer is built on 11 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 9 in Q1 journals, collectively cited 333 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 71 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions